TNF and Crohn disease: For instance, the STORI trial, a multicenter, prospective study specifically designed to assess the risk of relapse following the withdrawal of anti-TNF maintenance therapy in patients with luminal Crohn’s disease (CD) excluding perianal disease, observed relapse rates of 43.9% ± 5.2% at 12 months and 52.2% ± 5.2% at 24 months, with a median time to relapse of 16.4 months [9].